Alto Neuroscience (ANRO) EBIT (2023 - 2026)

Alto Neuroscience has reported EBIT for 4 years, with the latest figure at -$27.1 million in Q1 2026.

• Quarterly EBIT fell 73.12% year-over-year to -$27.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$77.8 million (down 11.34% YoY) and the FY2025 annual result came in at -$66.4 million, up 3.27% from the prior year.
• EBIT eased to -$27.1 million in Q1 2026 per ANRO's latest filing, from -$17.1 million in the prior quarter.
• Over five years, EBIT peaked at -$7.2 million in Q1 2023 and troughed at -$27.1 million in Q1 2026.
• A 4-year average of -$15.4 million and a median of -$15.7 million in 2025 frame the typical range for EBIT.
• The sharpest annual moves came in 2024 and 2025: EBIT sank 101.0% in 2024, then climbed 20.84% in 2025.
• Over 4 years, EBIT stood at -$11.8 million in 2023, then slumped by 44.47% to -$17.0 million in 2024, then fell by 0.34% to -$17.1 million in 2025, then slumped by 59.12% to -$27.1 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$27.1 million, -$17.1 million, and -$15.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.